Tegmine Therapeutics is a San Francisco-based biotech company that specializes in eradicating cancer through the development of revolutionary glycoprotein-targeting antibodies. Their proprietary TegMiner platform enables the discovery of unique cancer epitopes, leading to the creation of highly effective antibody-based therapies that minimize toxic side effects.
With a team of experienced professionals, including CEO Jeff Bernstein, PhD, and CTO Daniel Hyduke, PhD, Tegmine Therapeutics is at the forefront of developing pre-clinical stage cancer drug leads and advancing process development for clinical stage therapeutics. Through their innovative approach, Tegmine Therapeutics is dedicated to providing life-changing solutions for patients with unmet needs in the fight against cancer.
Generated from the website